Literature DB >> 16464403

The evolution of chemoradiation for glioblastoma: a modern success story.

René-Olivier Mirimanoff1.   

Abstract

The dismal prognosis of glioblastoma had remained unchanged for the past 30 years until the association of temozolomide and radiotherapy in the breakthrough European Organization for Cancer/National Cancer Institute of Canada (EORTC/NCIC) trial brought new hope for patients. This trial will serve as a platform for new and exciting clinical and translational research areas. We review here the role of standard radiotherapy and chemotherapy in glioblastoma and the potential causes of their failure, and we focus on some of the aspects that led to the successful EORTC/NCIC trial and some of the related studies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16464403     DOI： 10.1007/s11912-006-0009-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  16 in total

1.  Survival of human glioma cells treated with various combination of temozolomide and X-rays.

Authors:  J van Rijn; J J Heimans; J van den Berg; P van der Valk; B J Slotman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

Review 2.  Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.

Authors:  Normand Laperriere; Lisa Zuraw; Gregory Cairncross
Journal:  Radiother Oncol       Date:  2002-09       Impact factor: 6.280

3.  Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.

Authors:  Wolfgang Wick; Antje Wick; Jörg B Schulz; Johannes Dichgans; Hans P Rodemann; Michael Weller
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

4.  Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study.

Authors:  D G González; J Menten; D A Bosch; E van der Schueren; D Troost; M C Hulshof; J Bernier
Journal:  Radiother Oncol       Date:  1994-08       Impact factor: 6.280

5.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

Authors:  Helen Athanassiou; Maria Synodinou; Evagelos Maragoudakis; Mihalis Paraskevaidis; Cosmas Verigos; Despina Misailidou; Dosia Antonadou; George Saris; Konstantinos Beroukas; Pantelis Karageorgis
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures.

Authors:  A I Qureshi; M F Suri; J Khan; M Sharma; K Olson; L R Guterman; L N Hopkins
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

8.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Authors:  Roger Stupp; Pierre-Yves Dietrich; Sandrine Ostermann Kraljevic; Alessia Pica; Ivan Maillard; Phillipe Maeder; Reto Meuli; Robert Janzer; Gianpaolo Pizzolato; Raymond Miralbell; François Porchet; Luca Regli; Nicolas de Tribolet; René O Mirimanoff; Serge Leyvraz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 9.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

10.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506
View more
  3 in total

1.  Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.

Authors:  Nadia Malkoun; Cyrus Chargari; Fabien Forest; Marie-Jeannette Fotso; Lysian Cartier; Pierre Auberdiac; Julie Thorin; Cécile Pacaut; Michel Peoc'h; Christophe Nuti; Thierry Schmitt; Nicolas Magné
Journal:  J Neurooncol       Date:  2011-07-02       Impact factor: 4.130

Review 2.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 3.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.